BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Sarcomas AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
369 results:

  • 1. Temporal trends and regional variability in braf and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicine.
    Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
    Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Association of MDM2 Overexpression in Ameloblastomas with
    Tosios KI; Kalogirou EM; Koutlas IG
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. CD30 expression in an emerging group of mesenchymal spindle cell neoplasms with ALK fusion detected by flow cytometry and immunohistochemistry.
    Iwakoshi A; Kikui H; Nakashima R; Goto Y; Ichikawa D; Sasaki E; Sekimizu M; Hattori H; Maeda N
    Genes Chromosomes Cancer; 2024 Feb; 63(2):e23228. PubMed ID: 38380728
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Clinical features and mutation analysis of class 1/2/3 braf mutation colorectal cancer.
    Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
    Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Using tumor habitat-derived radiomic analysis during pretreatment
    Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
    Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Progress of braf Gene Alteration in Non-small Cell Lung Cancer].
    Deng L; Yang Y; Huang J
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):73-80. PubMed ID: 38296628
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Efficacy and safety of 'Second Adjuvant' therapy with braf/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
    Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
    Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Recent Advances in the Diagnosis, Pathogenesis, and Management of Myxoinflammatory Fibroblastic Sarcoma.
    Nishio J; Nakayama S; Aoki M
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256198
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence.
    Benhima N; Belbaraka R; Langouo Fontsa MD
    Curr Opin Oncol; 2024 Mar; 36(2):69-73. PubMed ID: 38193381
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres.
    Pallocca M; Molineris I; Berrino E; Marcozzi B; Betti M; Levati L; D'Atri S; Menin C; Madonna G; Ghiorzo P; Bulgarelli J; Ferraresi V; Venesio T; Rodolfo M; Rivoltini L; Lanfrancone L; Ascierto PA; Mazzarella L; Pelicci PG; De Maria R; Ciliberto G; Medico E; Russo G
    J Transl Med; 2024 Jan; 22(1):29. PubMed ID: 38184610
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Sequential immunotherapy and targeted therapy for metastatic braf V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
    Ascierto PA; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Cao MG; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Dummer R; Sileni VC; Palmieri G
    Nat Commun; 2024 Jan; 15(1):146. PubMed ID: 38167503
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Repurposing Metabolic Inhibitors in the treatment of Colon Adenocarcinoma Patient-Derived Models.
    Lee B; Lee C; Moon HM; Jo SY; Jang SJ; Suh YA
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132178
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A rare case of primary central nervous system histiocytic sarcoma harboring a novel ARHGAP45::braf fusion: a case report and literature review.
    Zhang L; Zhang G; Zheng H; Jiang B; Ju Y; Duan Q; An L; Shi H
    Brain Tumor Pathol; 2024 Jan; 41(1):18-29. PubMed ID: 38100030
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. treatment of acral and mucosal melanoma: Current and emerging targeted therapies.
    Zhang J; Tian H; Mao L; Si L
    Crit Rev Oncol Hematol; 2024 Jan; 193():104221. PubMed ID: 38036156
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Management of Brain Metastases: A Review of Novel Therapies.
    Bellur S; Khosla AA; Ozair A; Kotecha R; McDermott MW; Ahluwalia MS
    Semin Neurol; 2023 Dec; 43(6):845-858. PubMed ID: 38011864
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Research Progress of braf Fusion in Non-small Cell Lung Cancer].
    Xiao P; Zhong D
    Zhongguo Fei Ai Za Zhi; 2023 Oct; 26(10):782-788. PubMed ID: 37989341
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report.
    Hagihara Y; Suetsugu T; Uto H; Kozono T; Masada Y; Satozono Y; Shinmura M; Koreeda Y; Mizuno K; Inoue H
    Respir Investig; 2024 Jan; 62(1):13-15. PubMed ID: 37925883
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Long term activity of vemurafenib in cancers with braf mutations: the ACSE basket study for advanced cancers other than braf
    Blay JY; Cropet C; Mansard S; Loriot Y; De La Fouchardière C; Haroche J; Topart D; Tougeron D; You B; Italiano A; Le Brun-Ly V; Ferrero JM; Penel N; Fabbro M; Troussard X; Malka D; Ray-Coquard I; Leboulleux S; Fléchon A; Maubec E; Charles J; Dalle S; Taieb S; Garcia GCTE; Mandache AM; Colignon N; Gavrel M; Nowak F; Hoog Labouret N; Mahier Aït Oukhatar C; Gomez-Roca C
    ESMO Open; 2023 Dec; 8(6):102038. PubMed ID: 37922690
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Development and adaptations of the Graded Prognostic Assessment (GPA) scale: a systematic review.
    Ribeiro LM; Bomtempo FF; Rocha RB; Telles JPM; Neto EB; Figueiredo EG
    Clin Exp Metastasis; 2023 Dec; 40(6):445-463. PubMed ID: 37819546
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. KZ02 enhances the radiosensitivity of braf-mutated CRC in vitro and in vivo.
    Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
    Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 19.